Next-generation solutions for guided treatment decision support
MolecularHealth announces the commercialization and anticipated roll-out of two next-generation product lines that translate patient-specific molecular and genomic data, clinical history and published scientific evidence so that safer, more effective drug choices can be made for patients. Both product lines, one of which is Molecular Analysis of Side Effects (MASE), will be launched in drug safety and molecularly guided treatment decision support. MASE will combine adverse event information and clinicomolecular knowledge within a patient. The treatment decision support solutions will be available for oncological use initially.